SCHEMBL5537433

SCHEMBL5537433

CCOc1cccc2[c]occ12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.45
ALDH1A1 P00352 2/20 0.40
MAPT P10636 4/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
KDM4E B2RXH2 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
PABPC1 P11940 1/20 0.38
L3MBTL1 Q9Y468 7/20 0.36
NPSR1 Q6W5P4 1/20 0.36
GLA P06280 1/20 0.36
GRK6 P43250 1/20 0.35
ENPP1 P22413 1/20 0.35
GRM5 P41594 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C19 P33261 1/20 0.34
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.34
GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4473636 0.79 CA1 (0.41) CYP2A6ALDH1A1MAPTMEN1KMT2A
SCHEMBL30503999 0.74 ALDH1A1 (0.54) CYP2A6ALDH1A1MAPTMEN1KMT2A
SCHEMBL3818341 0.74 ALDH1A1 (0.54) CYP2A6ALDH1A1MAPTMEN1KMT2A
SCHEMBL5536683 0.72 GABRA1 (0.40) ALDH1A1L3MBTL1LMNA
SCHEMBL5548427 0.71 ALDH1A1 (0.44) CYP2A6ALDH1A1MAPTMEN1KMT2A
SCHEMBL2232272 0.71 CYP2A6 (0.41) CYP2A6ALDH1A1MAPTMEN1KMT2A
SCHEMBL5542072 0.70 CYP2A6 (0.41) CYP2A6ALDH1A1MAPTMEN1KMT2A
SCHEMBL5541323 0.68 GABRA1 (0.40) CYP1A2LMNA
SCHEMBL2257840 0.68 ALDH1A1 (0.41) CYP2A6ALDH1A1MAPTL3MBTL1NPSR1
SCHEMBL15772901 0.67 SYK (0.47) CYP2A6ALDH1A1MAPTKDM4ENPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 CYP2A6 1119/4885ALDH1A1 355/4885MAPT 4117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.